SynthesisAnatolian journal of cardiology2025
Myval versus Contemporary Valves in Patients Undergoing Transcatheter Aortic Valve Implantation: A Systematic Review and Meta-Analysis.
Synthesis in Anatolian journal of cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- TAVI in Patients with Large Aortic Annuli: A Single-Center Experience with Balloon-Expandable Valves.Anatolian journal of cardiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMyval is a balloon-expandable valve (BEV) used in transcatheter aortic valve implantation (TAVI) with distinguished features. Data comparing Myval with contemporary transcatheter heart valves (THVs) is limited. The authors performed a meta-analysis of studies comparing Myval with contemporary THVs (Sapien series and Evolut series).
methodsThe authors searched PubMed, EMBASE, and Cochrane databases. The primary composite endpoint of early safety (freedom from death and major complications) and other outcomes were extracted as defined by the Valve Academic Research Consortium 3 (VARC 3). The authors computed risk ratios (RRs) with 95% CIs using a Mantel-Haenszel method with a random-effects model with Review Manager (Cochrane Collaboration).
resultsSix studies with 2084 patients were included. Myval had better early safety at 30 days as per VARC 3 (RR 1.12; 95% CI: 1.02-1.22; P = .01) and lower need for permanent pacemaker implantation (PPI) (RR 0.62; 95% CI: 0.45-0.86; P = .004). Other outcomes were comparable in both groups. Vis-à-vis Evolut, Myval had better 30-day device success and lower rates of moderate or severe paravalvular leak (PVL) in addition to better early safety and lower need for PPI. Subgroup analyses of Myval with Sapien showed non-inferiority of Myval.
conclusionMyval showed better safety and lower need for PPI and may become a promising alternative for concurrent THVs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.